obesity. Obesity due to excess calories
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive dietary recommendations and boron citrate capsules including 10 mg boron for 12 weeks. Boron citrate capsules is made in Iran, a
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: BMI: 30–40 (kg/m²) Willingness to participate in the study
Exclusion criteria
Exclusion criteria: Athlete, pregnancy, lactation and menopause in women Under infertility treatment, taking birth control pills and estrogen Smoking and history of alcohol consumption Following a special diet three months before the study Use of chemical or herbal drugs for weight loss and use of hepatotoxic drugs such as phenytoin, amoxifene, lithium, blood pressure control drugs and blood lipid lowering drugs (statins), drugs that increase insulin sensitivity. Taking antibiotics or supplements affecting liver enzyme levels Weight loss surgery in the last year or strict weight loss diets in the last three months Using corticosteroid and non-steroidal anti-inflammatory drugs and any supplements for 3 months before the study or during the study Cardiovascular diseases, liver, kidney, intestinal, thyroid and parathyroid dysfunction, biliary disease, known autoimmune diseases, polycystic ovary syndrome, cancers and malabsorption diseases such as sprue and Crohn's Having symptoms of infectious or inflammatory disease or recent surgery Performed or candidate for liver transplant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Beginning and end of the trial. Method of measurement: Weight scale.;Body mass index (BMI). Timepoint: Beginning and end of the trial. Method of measurement: Calculation based on formula.;Waist circumference (WC). Timepoint: Beginning and end of the trial. Method of measurement: Tape measure.;Waist to hip ratio (WHR). Timepoint: Beginning and end of the trial. Method of measurement: Calculation based on formula.;Waist to height ratio (WHtR). Timepoint: Beginning and end of the trial. Method of measurement: Calculation based on formula.;C-reactive protein (CRP). Timepoint: Beginning and end of the trial. Method of measurement: ELISA.;Tumor necrosis factor-a (TNF-a). Timepoint: Beginning and end of the trial. Method of measurement: ELISA.;Interleukin-10 (IL-10). Timepoint: Beginning and end of the trial. Method of measurement: ELISA.;Interleukin-6 (IL-6). Timepoint: Beginning and end of the trial. Method of measurement: ELISA.;Hip circumference (HC). Timepoint: Beginning and end of the trial. Method of measurement: Tape measure. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood sugar (FBS). Timepoint: Beginning and end of the trial. Method of measurement: Use of an enzymatic kit method.;Fasting insulin levels. Timepoint: Beginning and end of the trial. Method of measurement: ELISA.;Insulin resistance with HOMA-IR score. Timepoint: Beginning and end of the trial. Method of measurement: Calculation based on formula.;Low density lipoprotein cholesterol (LDL-c). Timepoint: Beginning and end of the trial. Method of measurement: Calculation based on the Friedewald formula.;High density lipoprotein cholesterol (HDL-c). Timepoint: Beginning and end of the trial. Method of measurement: Use of an enzymatic kit method.;Total cholesterol (TC). Timepoint: Beginning and end of the trial. Method of measurement: Use of an enzymatic kit method.;Triglyceride (TG). Timepoint: Beginning and end of the trial. Method of measurement: Use of an enzymatic kit method.;Systolic blood pressure (SBP). Timepoint: Beginning and end of the trial. Method of measurement: Mercury manometer.;Diastolic blood pressure (DBP). Timepoint: Beginning and end of the trial. Method of measurement: Mercury manometer.;Quantitative insulin sensitivity check index (QUICKI). Timepoint: Beginning and end of the trial. Method of measurement: Calculation based on formula.;Serum level of triiodothyronine (T3). Timepoint: Beginning and end of the trial. Method of measurement: ELISA.;Serum level of tetraiodothyronine (T4). Timepoint: Beginning and end of the trial. Method of measurement: ELISA.;Serum level of thyroid Stimulating hormone (TSH). Timepoint: Beginning and end of the trial. Method of measurement: ELISA.;Prooxidant - Antioxidant balance (PAB). Timepoint: Beginning and end of the trial. Method of measurement: ELISA.;Superoxide dismutase (SOD). Timepoint: Beginning and end of the trial. Method of measurement: Spectrophotometric method and the Randox kit.;Glutathione Peroxidase (GPX). Timepoint: Beginning and end of the trial. Method of measurement: Spectrophotometricmetho | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHelda Tutunchi
Tabriz University of Medical Sciences
Outcome results
None listed